Rapamycin Derivatives for FTLD-U TDP-43 Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) lack effective therapies to address cognitive impairment and motor function deficiencies, with existing drugs like rapamycin showing mixed results and potential exacerbation of symptoms in some cases.
Innovation Solution
Administering rapamycin or its derivatives to decrease ubiquitinated TAR DNA-binding protein of 43 kDa (TDP-43) levels in the brain, thereby improving learning, memory, and motor functions in FTLD-U patients, and using autophagy inducers to reduce TDP-43 aggregation forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If rapamycin is administered to treat FTLD-U, then TDP-43 ubiquitination is reduced, but motor function may be exacerbated in some cases
Solution Approach 1:
The patent changes the chemical parameters of rapamycin by creating derivatives with modified side chains (e.g., changing the fatty acid moiety at the C-40 position). This parameter modification allows optimization of the drug's pharmacological profile to reduce TDP-43 ubiquitination while minimizing adverse effects on motor function, thereby resolving the contradiction between therapeutic efficacy and safety.
2Adaptability or versatility
If existing drugs are used to treat FTLD-U, then some cognitive symptoms may be addressed, but effective therapy for cognitive impairment and motor function deficiencies is lacking
Solution Approach 1:
The patent systematically modifies rapamycin's chemical structure by changing key parameters such as the fatty acid side chain length, saturation, and position to create a series of derivatives. This parameter optimization enables the discovery of compounds with enhanced therapeutic effectiveness for both cognitive and motor symptoms of FTLD-U, overcoming the limitations of existing drugs.
3Stability of the object's composition
If rapamycin treatment is applied, then TDP-43 mislocalization is reduced, but the amount of full-length TDP-43 remains unaffected
Solution Approach 1:
The patent uses rapamycin and its derivatives as intermediary agents that specifically target the ubiquitination pathway and protein aggregation processes. These intermediaries facilitate the redistribution of TDP-43 from cytoplasmic aggregates back to the nucleus without directly affecting the overall synthesis or degradation of full-length TDP-43, thus resolving the contradiction between improving distribution and maintaining total protein levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Rapamycin treatment effectively rescues learning and motor function deficits in FTLD-U mice by decreasing TDP-43 ubiquitination and promoting autophagic clearance, while autophagy inducers further enhance these benefits by reducing TDP-43 aggregation, improving cognitive and motor performance without adverse effects.
Implementation Method 1
Rapamycin treatment effectively rescues learning and motor function deficits in FTLD-U mice by decreasing TDP-43 ubiquitination and promoting autophagic clearance
Data Source
AI summary
Methods for rescuing learning, memory and/or motor function deficits associated with frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) are disclosed. The method comprises: a) administering to an animal having FTLD-U a therapeutically effective amount of an autophagy inducer; b) causing a decrease in the amount of ubiquitinated TDP-43 aggregation forms in the brain of the animal; and c) causing an improvement of the learning, memory capacities and/or motor function of the animal.